⚕️ The information below is for educational purposes only. It is not intended as a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition.
Two injectable weight-loss and diabetes medications dominate conversations in Indian endocrinology clinics and online communities: Ozempic (semaglutide) and Mounjaro (tirzepatide). Both are approved for Type 2 diabetes and increasingly used for weight management. Both are available in India. But which one is right for you?
This guide compares them across efficacy, safety, cost, availability, and practical Indian considerations — so you can have an informed conversation with your doctor.
Consult your healthcare provider before starting any medication. Do not switch or start medications without medical supervision.
Ozempic (semaglutide) is a GLP-1 receptor agonist — it mimics the GLP-1 hormone to slow gastric emptying, suppress appetite, and stimulate insulin release. Manufactured by Novo Nordisk. Available in India in 0.25, 0.5, 1, and 2 mg weekly injections (Ozempic pen), oral tablet (Rybelsus 3/7/14 mg), and Wegovy (higher-dose obesity formulation, limited availability in India).
Mounjaro (tirzepatide) is a dual GIP/GLP-1 receptor agonist — it activates both the GLP-1 and GIP (glucose-dependent insulinotropic polypeptide) receptors simultaneously. This dual action is why tirzepatide produces greater weight loss and HbA1c reduction compared to GLP-1 agonists alone. Manufactured by Eli Lilly. Available in India in 2.5, 5, 7.5, 10, 12.5, and 15 mg weekly injections.
The SURPASS-2 trial directly compared tirzepatide versus semaglutide 1 mg in Type 2 diabetes patients. This is the most important head-to-head data available:
| Outcome | Tirzepatide 10 mg | Tirzepatide 15 mg | Semaglutide 1 mg |
|---|---|---|---|
| HbA1c reduction | -2.37% | -2.46% | -1.86% |
| Body weight loss | -9.3 kg | -11.2 kg | -5.7 kg |
| Reached HbA1c < 7% | 82% | 86% | 79% |
| Reached HbA1c < 5.7% (normal range) | 27% | 31% | 15% |
Key finding: Tirzepatide achieved approximately twice the weight loss of semaglutide 1 mg, with a larger HbA1c reduction.
For obesity (without diabetes), the SURMOUNT-1 trial (tirzepatide) versus STEP-1 (semaglutide 2.4 mg) showed:
| Drug | Average Weight Loss (% body weight) |
|---|---|
| Tirzepatide 15 mg | ~22.5% |
| Semaglutide 2.4 mg (Wegovy) | ~15% |
Tirzepatide produces meaningfully more weight loss than semaglutide — approximately 7–8% more of body weight over 68–72 weeks.
Both drugs share a similar gastrointestinal side effect profile. Nausea, diarrhoea, vomiting, and constipation are the most common issues for both.
| Side Effect | Ozempic (semaglutide) | Mounjaro (tirzepatide) |
|---|---|---|
| Nausea | Very common (15–44%) | Very common (17–31%) |
| Diarrhoea | Common (14–30%) | Common (12–17%) |
| Vomiting | Common (5–24%) | Common (6–10%) |
| Constipation | Common (5–14%) | Common (11–17%) |
| Injection site reactions | Occasional | Occasional |
| Pancreatitis risk | Rare but listed | Rare but listed |
| Thyroid C-cell risk | Black Box warning (rodents) | Black Box warning (rodents) |
| Hypoglycaemia (with insulin) | Low alone, moderate combined | Low alone, moderate combined |
Practical observation: Many Indian users report that tirzepatide's nausea profile is slightly more tolerable than semaglutide at equivalent therapeutic doses — though this is not consistently shown in trials and may reflect dose-finding and titration differences.
| Drug | Available in India? | Brands | Source |
|---|---|---|---|
| Semaglutide injectable | Yes | Ozempic (Novo Nordisk India) | Licensed pharmacies nationwide |
| Semaglutide oral | Yes | Rybelsus (Novo Nordisk India) | Licensed pharmacies nationwide |
| Tirzepatide injectable | Yes (limited) | Mounjaro (Eli Lilly India) | Selected cities, specialist centres |
Mounjaro was approved by CDSCO for Type 2 diabetes in India in 2024. Availability is currently concentrated in metro cities (Mumbai, Delhi, Bengaluru, Hyderabad, Chennai). Supply can be inconsistent in Tier-2 cities — check with your endocrinologist for local availability before assuming you can source it.
| Drug | Dose | Approximate Monthly Cost |
|---|---|---|
| Ozempic 0.5 mg/week | 4 injections | ₹10,000–13,000 |
| Ozempic 1 mg/week | 4 injections | ₹12,000–16,000 |
| Rybelsus 14 mg/day | 30 tablets | ₹5,500–7,000 |
| Mounjaro 5 mg/week | 4 injections | ₹12,000–15,000 |
| Mounjaro 10 mg/week | 4 injections | ₹14,000–18,000 |
| Mounjaro 15 mg/week | 4 injections | ₹16,000–22,000 |
Tirzepatide at full therapeutic dose (10–15 mg) is somewhat more expensive than semaglutide 1 mg, but the greater efficacy per rupee spent may justify the additional cost for some patients — particularly those who did not respond well to semaglutide.
Both are highly effective for Type 2 diabetes. Tirzepatide demonstrates superior HbA1c reduction across all doses in head-to-head trials. However:
For weight loss, tirzepatide wins on efficacy — approximately 22.5% body weight loss vs 15% for semaglutide 2.4 mg over about 68–72 weeks. For a 90 kg Indian patient:
This is a meaningful clinical difference. If significant weight loss is the primary goal and you can access and afford tirzepatide, the efficacy data supports it.
Both drugs share essentially the same contraindication profile:
There is no meaningful difference in contraindications between the two.
Storage in Indian heat: Both require refrigeration (2–8°C). Once in use, Ozempic pens can be kept at room temperature up to 30°C for 6 weeks; Mounjaro pens for up to 21 days. In summer, use a portable vaccine carrier or cooler bag when travelling.
Injection technique: Both are weekly subcutaneous injections into the abdomen, thigh, or upper arm. Rotate injection sites to avoid lipohypertrophy.
Combination with other diabetes medications: Both work well alongside metformin (the backbone of Indian T2D treatment). Combining with sulfonylureas or insulin increases hypoglycaemia risk — your doctor will likely reduce those doses.
Pregnancy planning: Both must be stopped at least 2 months before trying to conceive. Discuss with your endocrinologist if you are planning pregnancy.
Q: Can I switch from Ozempic to Mounjaro? Yes, this is done in clinical practice when patients have plateaued on semaglutide or need better glycaemic control. Your doctor will guide the transition — typically stopping semaglutide and starting tirzepatide at the lowest dose with re-titration.
Q: Is Mounjaro approved in India? Yes. Tirzepatide (Mounjaro) received CDSCO approval for Type 2 diabetes in India in 2024. It is not yet approved in India specifically for obesity (though it is used off-label for this indication by specialists).
Q: Does tirzepatide have cardiovascular evidence like semaglutide? Semaglutide has strong cardiovascular outcome trial data (SUSTAIN-6, FLOW). Tirzepatide's cardiovascular outcomes trial (SURPASS-CVOT) is ongoing. For patients with established cardiovascular disease, semaglutide currently has a stronger evidence base.
Q: Which has fewer side effects? Both have similar GI side effect profiles. Individual tolerability varies — some people tolerate one better than the other. If you experience intolerable side effects on one, switching may help.
This article is for informational purposes only. Consult your healthcare provider before starting any medication. Do not switch medications without medical supervision.
